Co-Diagnostics Statistics
Total Valuation
Co-Diagnostics has a market cap or net worth of $11.19 million. The enterprise value is $4.97 million.
Important Dates
The next estimated earnings date is Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Co-Diagnostics has 3.66 million shares outstanding. The number of shares has increased by 57.98% in one year.
| Current Share Class | 3.66M |
| Shares Outstanding | 3.66M |
| Shares Change (YoY) | +57.98% |
| Shares Change (QoQ) | +19.63% |
| Owned by Insiders (%) | 3.19% |
| Owned by Institutions (%) | 9.56% |
| Float | 3.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.55 |
| Forward PS | 26.21 |
| PB Ratio | 0.69 |
| P/TBV Ratio | 1.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.28, with a Debt / Equity ratio of 0.13.
| Current Ratio | 2.28 |
| Quick Ratio | 1.94 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -151.66% and return on invested capital (ROIC) is -322.26%.
| Return on Equity (ROE) | -151.66% |
| Return on Assets (ROA) | -52.09% |
| Return on Invested Capital (ROIC) | -322.26% |
| Return on Capital Employed (ROCE) | -185.53% |
| Weighted Average Cost of Capital (WACC) | 16.40% |
| Revenue Per Employee | $6,245 |
| Profits Per Employee | -$421,763 |
| Employee Count | 115 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.41 |
Taxes
| Income Tax | -1.63M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.08% in the last 52 weeks. The beta is 2.75, so Co-Diagnostics's price volatility has been higher than the market average.
| Beta (5Y) | 2.75 |
| 52-Week Price Change | -63.08% |
| 50-Day Moving Average | 3.40 |
| 200-Day Moving Average | 6.18 |
| Relative Strength Index (RSI) | 43.56 |
| Average Volume (20 Days) | 1,004,945 |
Short Selling Information
The latest short interest is 349,389, so 9.55% of the outstanding shares have been sold short.
| Short Interest | 349,389 |
| Short Previous Month | 194,179 |
| Short % of Shares Out | 9.55% |
| Short % of Float | 9.87% |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of $718,166 and -$48.50 million in losses. Loss per share was -$29.82.
| Revenue | 718,166 |
| Gross Profit | 323,611 |
| Operating Income | -31.94M |
| Pretax Income | -50.13M |
| Net Income | -48.50M |
| EBITDA | -30.86M |
| EBIT | -31.94M |
| Loss Per Share | -$29.82 |
Full Income StatementBalance Sheet
The company has $8.23 million in cash and $2.03 million in debt, giving a net cash position of $6.20 million or $1.70 per share.
| Cash & Cash Equivalents | 8.23M |
| Total Debt | 2.03M |
| Net Cash | 6.20M |
| Net Cash Per Share | $1.70 |
| Equity (Book Value) | 16.04M |
| Book Value Per Share | 4.45 |
| Working Capital | 5.50M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$28.24 million and capital expenditures -$750,151, giving a free cash flow of -$28.99 million.
| Operating Cash Flow | -28.24M |
| Capital Expenditures | -750,151 |
| Depreciation & Amortization | 1.08M |
| Net Borrowing | n/a |
| Free Cash Flow | -28.99M |
| FCF Per Share | -$7.93 |
Full Cash Flow StatementMargins
| Gross Margin | 45.06% |
| Operating Margin | -4,447.41% |
| Pretax Margin | -6,980.30% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |